Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05361395 · ClinicalTrials.gov registry record · Phase 1

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

A Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.

Active
Registry status
Phase 1
Development phase
184
Enrollment target
20
Study locations

NCT05361395 is a Phase 1 study of Extensive-stage Small-cell Lung Cancer that is active but no longer recruiting, run by Amgen. The registered enrollment target is 184 participants, above the 168-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05361395, a Phase 1 study of Extensive-stage Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Amgen.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
184 participants
Enrollment target
20
Study locations

Study Summary

This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

Conditions Studied

Extensive-stage Small-cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Atezolizumab
  • DRUG Etoposide
  • DRUG Durvalumab
  • DRUG Tarlatamab

Study Locations (20)

Other

  • Universitair Ziekenhuis Antwerpen - Edegem
  • Algemeen Ziekenhuis Maria Middelares - Ghent
  • Jessa Ziekenhuis - Campus Virga Jesse - Hasselt
  • AZ Delta Campus Rumbeke - Roeselare
  • Rigshospitalet - Copenhagen
  • Centre Leon Berard - Lyon
  • Centre Hospitalier Universitaire de Nantes, Hôpital Nord Laënnec - Saint-Herblain
  • Gustave Roussy - Villejuif

California

  • University of Southern California, Norris Comprehensive Cancer Center - Los Angeles

Delaware

  • Christiana Care Health Services - Newark

Michigan

  • Henry Ford Health System - Detroit

New Jersey

  • Rutgers Cancer Institute of New Jersey - New Brunswick

New York

  • New York University Grossman School of Medicine and New York University Langone Hospitals - New York

North Carolina

  • The University of North Carolina at Chapel Hill - Chapel Hill

South Dakota

  • Avera Cancer Institute - Sioux Falls

Trial Details

FieldValue
Enrollment Target 184 participants
Start Date 2022-08-24
Est. Completion 2028-08-28
Phase Phase 1

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05361395

The ClinicalTrials.gov registry entry for NCT05361395 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 168-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (10% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT05361395 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Delaware.

Frequently Asked Questions

What is clinical trial NCT05361395 about?

NCT05361395 is a clinical study titled "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)". This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

What is the current status of trial NCT05361395?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 184 participants. The study started on 2022-08-24. Estimated completion is 2028-08-28.

What conditions does trial NCT05361395 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT05361395?

The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Etoposide (DRUG), Durvalumab (DRUG), Tarlatamab (DRUG).

Who is sponsoring clinical trial NCT05361395?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05361395 being conducted?

This trial has 20 study locations across California, Delaware, Michigan, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Extensive-stage Small-cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.